China is fast becoming a major player in the global pharmaceutical and biotech industries. Once focused primarily on generic and me-too drugs, Chinese companies are now making headlines with innovative breakthroughs in oncology and gene therapy. Foreign investors are taking notice, pouring billions into partnerships and research projects across the country. But can China maintain this momentum — or will political pressure and consumer skepticism slow things down?Skip Montreux and Dez Morgan explore how China’s pharmaceutical and biotech sectors are reshaping the global healthcare landscape. They trace the industry’s evolution from state-run factories to world-class R&D centers, discuss the surge in foreign investment, and introduce key players like Akeso Biopharma. Along the way, they also unpack some of the challenges that may lie ahead for this fast-growing industry.D2B 364 investigates China’s pharmaceutical transformation — from copycat drugs to cutting-edge therapies — and asks what it means for the future of global medicine and investment trends.Do you like what you hear?Become a D2B Member today for to access to member-only episodes, our --NEW!!! -- INTERACTIVE AUDIO SCRIPTS, PDF Audio Script Library, Bonus Vocabulary episodes, and D2B Member-only episodes.Visit d2benglish.com/membership for more information.